IGF-binding protein 2 is a candidate target of therapeutic potential in cancer

Tumor Biology

Volumn 37, Issue 2, 2016, Pages 1451-1459

  Yao, Xiaofeng ^a,b   Sun, Shanshan ^a,b   Zhou, Xuan ^a,b   Guo, Wenyu ^a,b   Zhang, Lun ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Biomarker; IGFBP2; Metastasis; Target therapy; Tyrosine kinase inhibitor

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTISENSE OLIGONUCLEOTIDE; CIXUTUMUMAB; DALOTUZUMAB; DASATINIB; DOCETAXEL; INTEGRIN; OGX 225; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; R 1507; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CARCINOGENESIS; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESISTANCE; DRUG TARGETING; GLIOMA; HUMAN; LEUKEMIA; LUNG CANCER; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR GROWTH; ANIMAL; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84949521499     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4561-1     Document Type: Review

References (91)

1. Cao Y et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer. 2015;136(10):2418–26.
2. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 2008;8(12):915–28.
3. Šunderić M et al. Molecular forms of the insulin-like growth factor-binding protein-2 in patients with colorectal cancer. Exp Mol Pathol. 2014;96(1):48–53.
4. Ahani N et al. Expression of insulin-like growth factor binding protein-2 (IGFBP-2) gene in negative and positive human cytomegalovirus glioblastoma multiforme tissues. Med Oncol. 2014;31(2):812.
5. Kricker JA et al. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology. 2003;144(7):2807–15.
6. Fukushima T, Kataoka H. Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. Anticancer Res. 2007;27(6A):3685–92.
7. Rohrmann S et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European prospective investigation into cancer and nutrition. Br J Cancer. 2012;106(5):1004–10.
8. Rowlands MA et al. Serum insulin-like growth factors and mortality in localized and advanced clinically detected prostate cancer. Cancer Causes Control. 2012;23(2):347–54.
9. Liou JM et al. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and pognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 2010;95(4):1717–25.
10. Ma J et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst. 1999;91(7):620–5.
11. Miyake H et al. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep. 2005;13(2):341–5.
12. Wang H et al. Insulin-like growth factor binding protein2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 2003;63(15):4315–21.
13. Carrick FE et al. BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains. J Biol Chem. 2001;276(29):27120–8.
14. Headey SJ et al. Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding. J Mol Endocrinol. 2004;33(2):377–86.
15. Zesławski W et al. The interaction of insulin-like growth factor-1 with the N-terminal domain of IGFBP-5. EMBO J. 2001;20(14):3638–44.
16. Galea CA et al. Insulin-like growth factor binding protein-2: NMR analysis and structural characterization of the N-terminal domain. Biochimie. 2012;94(3):608–16.
17. Sitar T et al. Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A. 2006;103(35):13028–33.
18. Swain M et al. High-yield bacterial expression and structural characterization of recombinant human insulin-like growth factor binding protein-2. Arch Biochem Biophys. 2010;501(2):195–200.
19. Holmes KM et al. Insulin-like growth factor-binding protein 2-driven glioma progression isprevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kB network. Proc Natl Acad Sci U S A. 2012;109(9):3475–80.
20. Wheatcroft SB et al. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and −2: implications for metabolic homeostasis. Trends Endocrinol Metab. 2009;20(4):153–62.
21. Kawai M et al. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem. 2011;286(16):14670–80.
22. Mehrian-Shai R et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A. 2007;104(13):5563–8.
23. Dunlap SM et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A. 2007;104(28):11736–41.
24. Han S et al. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway. Br J Cancer. 2014;111(7):1400–9.
25. Moore LM et al. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A. 2009;106(39):16675–79.
26. Song SW et al. IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc Natl Acad Sci U S A. 2003;100(24):13970–5.
27. Biernacka KM et al. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer. 2013;20(5):741–51.
28. Uzoh CC et al. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer. 2011;104(10):1587–93.
29. Neuhouser ML et al. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res. 2013;6(7):91–9.
30. Dean SJ et al. Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negativebreast cancer. Am J Clin Pathol. 2014;141(3):323–33.
31. So AI et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res. 2008;14(21):6944–54.
32. Migita T et al. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol. 2010;176(4):1756–66.
33. Zhang Y et al. Autoantibodies against insulin-like growth factor protein-2 as a serological biomarker in the diagnosis of lung cancer. Int J Oncol. 2013;42(1):93–100.
34. Kühnl A et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res. 2011;35(12):1585–90.
35. Dawczynski K et al. Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant. 2006;37(6):589–94.
36. Renehan AG et al. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer. 2000;83(10):1344–50.
37. Huang YF et al. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer. 2014;21(2):217–29.
38. Zhang L et al. Expression of IGFBP2 in gastric carcinoma and relationship with clinicpathologic parameters and cell proliferation. Dig Dis Sci. 2007;52(1):248–53.
39. Tombolan L et al. High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma. Am J Pathol. 2011;179(5):2611–24.
40. Wang H et al. Expression of insulin-like growth factorbinding protein 2 in melanocytic lesions. J Cutan Pathol. 2003;30(10):599–605.
41. Wang GK et al. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem. 2006;281(20):14085–91.
42. Mendes KN et al. JNK mediates insulin-like growth factor binding protein2/integrin alpha5-dependent glioma cell migration. Int J Oncol. 2010;37(1):143–53.
43. Hsieh D et al. IGFBP2 promotes glioma tumor stem cell expansion and survival. Biochem Biophys Res Commun. 2010;397(2):367–72.
44. Foulstone EJ et al. Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology. 2013;154(5):1780–93.
45. Lu H et al. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther. 2013;12(12):2864–73.
46. Chen X et al. IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells. J Hematol Oncol. 2013;6(1):72.
47. Ben-Shmuel A et al. Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression. Oncogene. 2013;32(27):3220–30.
48. Chakrabarty S, Kondratick L. Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther. 2006;5(2):189–97.
49. Lancaster JM et al. High expression of insulin-like growth factor binding protein–2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006;16(4):1529–35.
50. Kang Z et al. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. Oncogene. 2014;33(50):5697–705.
51. Das SK et al. MDA-9/Syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Res. 2013;73(2):844–54.
52. Wang HM et al. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008;14(3):261–7.
53. Wieczorek E et al. Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. Tumour Biol. 2015;36(1):163–75.
54. Verma S et al. Matrix metalloproteinases and gastrointestinal cancers: impacts of dietary antioxidants. World J Biol Chem. 2014;5(3):355–76.
55. Azar WJ et al. IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology. 152(9):3332–42.
56. Zhu Z et al. Inhibition of PKR impairs angiogenesis through VEGF pathway. Am J Physiol Endocrinol Metab. 2015;308(6):E518–24.
57. Godard S et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003;63(20):6613–25.
58. Jing T et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood. 2012;120(11):2330–9.
59. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–54.
60. Conover CA. Isulin-like growth factor-binding proteins and bone metabolism. Am J Physiol Endocrinol Metab. 2008;294(1):E10–4.
61. Shen X et al. Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol. 2012;32(20):4116–30.
62. Russo VC et al. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology. 2005;146(10):4445–55.
63. Lund J et al. Heparin-binding mechanism of the IGF2/IGF-binding protein 2 complex. J Mol Endocrinol. 2014;52(3):345–55.
64. Diehl D et al. IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer. 2009;124(9):2220–5.
65. Hang XP et al. Genetic variations in the IGF-IGFR-IGFBP axis confer susceptibility to lung and esophageal cancer. Genet Mol Res. 2014;13(1):2107–19.
66. Png KJ et al. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2011;481(7380):190–4.
67. Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev. 2012;38(4):292–302.
68. Zhang CC et al. Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation. Blood. 2008;111(7):3415–23.
69. Becher OJ et al. IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. J Child Neurol. 2008;23(10):1205–13.
70. Grimberg A et al. Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther. 2006;5(10):1408–14.
71. Fukushima T et al. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007;282(25):18634–44.
72. Sun C et al. PTEN regulation of the proliferation and differentiation of auditory progenitors through the PTEN/PI3K/Akt-signaling pathway in mice. Neuroreport. 2014;25(3):177–83.
73. Carnero A, Paramio JM. The PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol. 2014;23(4):252.
74. Mireuta M et al. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors. 2010;28(4):243–55.
75. Sheldrake HM, Patterson LH. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. J Med Chem. 2014;57(15):6301–15.
76. Sun CC et al. Integrins: players in cancer progression and targets in cancer therapy. Anticancer Drugs. 2014;25(10):1107–21.
77. Schütt BS et al. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol. 2004;32(3):859–68.
78. Wani AA et al. Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kB /interleukin-6 signaling pathway. Oncogene. 2011;30(24):2778–88.
79. Yang M et al. The role of integrin-β/FAK in cyclic mechanical stimulation in MG-63 cells. Int J Clin Exp Pathol. 2014;7(11):7451–9.
80. Cox BD et al. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem. 2006;99(1):35–52.
81. Monasor A et al. INK4a/ARF limits the expansion of cells suffering from replication stress. Cell Cycle. 2013;12(12):1948–54.
82. Tang MR et al. CD24 expression predicts poor prognosis for patients with cutaneous malignant melanoma. Int J Clin Exp Med. 2014;7(11):4337–41.
83. Wu JX et al. Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis. PLoS One. 2014;9(12):E114746.
84. Villani RM et al. Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting igfbp2 activity. Cancer Prev Res. 2010;3(10):1222–34.
85. Sineva GS, Pospelov VA. β-Catenin in pluripotency: adhering to self-renewal or wnting to differentiate. Int Rev Cell Mol Biol. 2014;312:53–78.
86. Sehgal P et al. Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis. Mol Cancer. 2013;12:63.
87. Miyako K et al. PAPA-1 is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol. 2009;23(2):169–75.
88. Brana I et al. A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014;111(10):1932–44.
89. Willky BA et al. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015;112(1):24–31.
90. Halvorson KG et al. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PLoS One. 2015;10(3):E0118926.
91. McCaffery I et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res. 2013;19(15):4282–9.